Omeros Corporation (OMER) News
Filter OMER News Items
OMER News Results
|Loading, please wait...|
Latest OMER News From Around the Web
Below are the latest news stories about Omeros Corp that investors may wish to consider to help them evaluate OMER as an investment opportunity.
E ratio of -3.56.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2021, which include
No summary available.
Omeros press release (OMER): Q4 Non-GAAP EPS of -$0.37 misses by $0.31.At December 31, 2021, Omeros had $157.3 million of cash, cash equivalents and short-term investments available…
Every investor in Omeros Corporation ( NASDAQ:OMER ) should be aware of the most powerful shareholder groups...
Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SEATTLE, February 24, 2022--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021, on Tuesday, March 1, 2022, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Omeros Corporation (NASDAQ:OMER)s traded shares stood at 0.34 million during the last session, with the companys beta value hitting 0.63. At the close of trading, the stocks price was $6.32, to imply a decrease of -1.86% or -$0.12 in intraday trading. The OMER shares 52-week high remains $23.85, putting it -277.37% down since that peak Omeros Corporation (NASDAQ: OMER) Has Fallen -277.37% From Its Highs, What Comes Next? Read More »
Investment company Bellevue Asset Management, Llc (Current Portfolio) buys First Trust Low Duration Mortgage Opportunities ET, eBay Inc, Omeros Corp, Realty Income Corp, Trane Technologies PLC, sells Bristol-Myers Squibb Co, General Electric Co, Timberland Bancorp Inc, Ford Motor Co, United Parcel Service Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Bellevue Asset Management, Llc.
Omeros Corporation (NASDAQ: OMER ) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory, and legal experts addressing the points raised Full story available on Benzinga.com